Try our Advanced Search for more refined results
MCDERMID v. INOVIO PHARMACEUTICALS, INC. et al
Case Number:
2:20-cv-01402
Court:
Nature of Suit:
Other Statutes: Securities/Commodities
Multi Party Litigation:
Class Action
Judge:
Firms
- Berger Montague
- Block & Leviton
- Cooley LLP
- Donovan Litigation
- Duane Morris
- Glancy Prongay
- Goldman Scarlato
- Kohn Swift
- Robbins Geller
- Sacks Weston
- Shuman Glenn
- Wolf Haldenstein
Companies
Sectors & Industries:
-
January 18, 2023
Investors, Inovio Get Final OK For $44M Deal In Stock Suit
A Pennsylvania federal judge on Wednesday approved a $44 million deal between biotechnology firm Inovio Pharmaceuticals Inc. and its investors to resolve claims that the company's alleged misrepresentation of its COVID-19 vaccine development efforts in early 2020 prompted its stock price to plunge.
-
August 23, 2022
Inovio Inks $44M Cash, Stock Deal To End COVID-19 Vax Suit
Biotechnology firm Inovio Pharmaceuticals Inc. has reached a $44 million settlement agreement with its investors, which if approved would end claims that the company's misrepresentation of its COVID-19 vaccine development efforts in early 2020 prompted its stock price to plunge.
-
January 24, 2022
Inovio Fights Investor Class Cert. In COVID-19 Vaccine Suit
Biotechnology firm Inovio Pharmaceuticals Inc. and a cohort of company executives doubled down on their arguments to a Pennsylvania federal court Friday and urged against class certification for investors bringing claims over the executives' statements on a coronavirus vaccine.
-
July 30, 2021
Inovio Investors Move For Cert. In COVID-19 Vaccine Suit
A class of investors moved for certification Thursday in their suit against biotechnology firm Inovio Pharmaceuticals Inc. and a cohort of company executives alleging that they misled the public about a coronavirus vaccine they purported to have in the works.
-
February 16, 2021
Inovio Must Face Trimmed Investor Claims Over Virus Vaccine
Biotechnology firm Inovio Pharmaceuticals Inc. and a cohort of company executives must face slightly trimmed class action claims alleging they misled the public about a coronavirus vaccine they purport to have in the works, a Pennsylvania federal judge ruled Tuesday.
-
December 22, 2020
Investors Slam Inovio's Bid To Duck COVID-19 Vaccine Suit
Biotechnology firm Inovio Pharmaceuticals Inc. and a cohort of company executives shouldn't be allowed to shake off a consolidated class action alleging they misled the public about a coronavirus vaccine they purport to have in the works, Inovio shareholders told a federal court in Philadelphia.
-
November 05, 2020
Inovio Defends Virus Vaccine Claims In Bid To Nix Stock Suit
Inovio Pharmaceuticals Inc. said Thursday that it has been entirely upfront with investors about its efforts to develop and produce a COVID-19 vaccine, contrary to the claims of a securities suit it wants dismissed.
-
June 19, 2020
Robbins Geller Will Lead Proposed Inovio Investor Class
Robbins Geller Rudman & Dowd LLP, with an assist from Saxton & Stump, will represent a proposed class of shareholders in a suit alleging Inovio Pharmaceuticals Inc. inflated its stock price by confusing the public with claims about a "three-hour" development timeline for a COVID-19 vaccine.
-
May 29, 2020
COVID-19 Securities Catch-Up: The 8 Biggest Investor Actions
At least 50 federal securities cases with references to COVID-19 have been filed in the past three months, including merger challenges, regulatory enforcement actions and sprawling investor suits, according to a Law360 review of filings. As the pandemic pushes into the summer, Law360 is taking a look at eight major investor actions that were brought in connection with the novel coronavirus since March.
-
May 13, 2020
9 Firms Vie For Lead Counsel In Inovio COVID-19 Vaccine Suit
Nine law firms including Block & Leviton LLP and The Rosen Law Firm PA are competing to be lead counsel in a proposed stock drop class action against Inovio Pharmaceuticals, where investors allege the biotech company's statements it was ready to test a COVID-19 vaccine inflated the stock price before the company walked the statements back.